Valvular heart disease
Conditions
Interventions
L-S-M biopsy:Patients with various cardiovascular diseases who plan to undergo endomyocardial biopsy and receive L-S-M biventricular biopsy.
Non L-S-M biopsy:Various cardiovascular disease patients who plan to undergo endomyocardial biopsy and undergo traditional biopsy forceps endomyocardial biopsy.
Sponsors
Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. >= 18 years old. 2. Patients with cardiomyopathy or arrhythmia who require endomyocardial biopsy according to the 2023 ESC management guidelines and the 2025 Chinese comprehensive management guidelines for cardiomyopathy. 3. Voluntarily participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals with severe coronary artery disease (with a clear history of recent severe coronary artery bypass surgery or percutaneous coronary intervention, and a clinical history of myocardial infarction within the past month). 2. Reject the endomyocardial biopsy technique. 3. Contraindications for endomyocardial biopsy, such as severe liver, lung, kidney dysfunction, bleeding disorders, severe thrombocytopenia, and those undergoing anticoagulant therapy. 4. Vulnerable groups, including individuals with mental illness, cognitive impairment, critically ill patients, minors, pregnant women, illiterate individuals, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of obtaining left and right myocardial biopsies, Surgical success rate, incidence of complications (pericardial tamponade, embolism, conduction block, etc.); | — |
Secondary
| Measure | Time frame |
|---|---|
| Additional assessment items for myocardial samples: 1. Outsourced multi-omics testing (1 time in total, approximately 10-50mg, for detecting proteins, metabolites, RNA, etc.). 2. Peripheral blood samples (1 time in total, approximately 2mL per time, for proteomics and metabolite detection).;Sample adequacy rate, tissue quality score, and accuracy of biopsy diagnosis.; | — |
Countries
China
Contacts
Public ContactYe Yang
Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed